ALX Oncology Holdings Inc.

NasdaqGS:ALXO Stock Report

Market Cap: US$28.5m

ALX Oncology Holdings Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

NasdaqGS:ALXO Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
19 Feb 25SellUS$2,483Jason LettmannIndividual2,159US$1.15
19 Feb 25SellUS$1,525Jaume PonsIndividual1,326US$1.15
19 Feb 25SellUS$633Shelly PintoIndividual550US$1.15
06 Jan 25SellUS$3,998Shelly PintoIndividual2,221US$1.80
30 Dec 24SellUS$17,060Jaume PonsIndividual10,796US$1.58
30 Dec 24SellUS$2,253Shelly PintoIndividual1,426US$1.58
02 Dec 24BuyUS$46,404Rekha HemrajaniIndividual30,000US$1.55
14 Aug 24SellUS$1,455Shelly PintoIndividual564US$2.58
14 Aug 24SellUS$4,997Jaume PonsIndividual1,937US$2.58
14 Aug 24SellUS$3,522Sophia RandolphIndividual1,365US$2.58
05 Jul 24SellUS$10,025Shelly PintoIndividual1,823US$5.50
01 Jul 24SellUS$62,599Jaume PonsIndividual10,758US$5.82
01 Jul 24SellUS$19,045Sophia RandolphIndividual3,273US$5.82
01 Jul 24SellUS$7,989Shelly PintoIndividual1,373US$5.82
13 Jun 24BuyUS$102,338Peter GarciaIndividual12,000US$8.53

Insider Trading Volume

Insider Buying: ALXO insiders have only sold shares in the past 3 months.

Ownership Breakdown

What is the ownership structure of ALXO?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders1,310,9702.46%
Hedge Funds3,689,6116.91%
General Public4,387,6068.22%
VC/PE Firms16,076,43430.1%
Institutions27,931,14952.3%

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.

Top Shareholders

Top 25 shareholders own 83.19% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
18.2%
venBio LLC
9,699,925US$5.2m0%3.98%
6.91%
Redmile Group, LLC
3,689,611US$2.0m-3.83%0.15%
6.42%
HBM Partners Ltd.
3,426,929US$1.8m0%0.19%
6.17%
Tang Capital Management, LLC
3,296,883US$1.8m-21.6%0.1%
5.52%
LSV Capital Management, LLC
2,949,580US$1.6m0%100.0%
4.33%
BlackRock, Inc.
2,313,800US$1.2m-2.95%no data
4.2%
Morgan Stanley, Investment Banking and Brokerage Investments
2,242,005US$1.2m812%no data
3.99%
Millennium Management LLC
2,129,110US$1.1m6.33%no data
3.53%
The Vanguard Group, Inc.
1,887,002US$1.0m0.13%no data
3.47%
FMR LLC
1,851,556US$986.7k-68.4%no data
2.61%
MPM BioImpact LLC
1,391,434US$741.5k-42.3%0.11%
2.29%
Almitas Capital LLC
1,222,945US$651.7k0%0.11%
2.08%
Acadian Asset Management LLC
1,109,448US$591.2k160%no data
1.94%
Bank of America Corporation, Asset Management Arm
1,035,226US$551.7k493%no data
1.55%
BMO Asset Management Corp.
826,582US$440.5k0%no data
1.54%
Two Sigma Advisers, LP
823,900US$439.1k64.6%no data
1.39%
Geode Capital Management, LLC
740,106US$394.4k5.6%no data
1.32%
Two Sigma Investments, LP
704,131US$375.2k6.68%no data
1.28%
State Street Global Advisors, Inc.
684,123US$364.6k1.9%no data
0.95%
Privium Fund Management BV
509,059US$271.3k0%0.05%
0.89%
Jaume Pons
473,513US$252.3k0.51%no data
0.76%
UBS Asset Management AG
408,056US$217.5k1,300%no data
0.68%
Goldman Sachs Group, Investment Banking and Securities Investments
360,498US$192.1k0%no data
0.64%
Northern Trust Global Investments
343,066US$182.8k7.29%no data
0.56%
Los Angeles Capital Management LLC
301,419US$160.6k16.9%no data

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/05 23:50
End of Day Share Price 2025/05/05 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

ALX Oncology Holdings Inc. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Alethia YoungCantor Fitzgerald & Co.
Li Wang WatsekCantor Fitzgerald & Co.
Martin AusterCredit Suisse